(0.19%) 5 141.25 points
(0.18%) 38 511 points
(0.27%) 17 894 points
(-0.93%) $83.07
(1.66%) $1.955
(-0.31%) $2 340.00
(0.80%) $27.47
(0.25%) $924.40
(-0.15%) $0.933
(-0.04%) $11.02
(-0.19%) $0.799
(0.99%) $92.79
@ $92.30
Utstedt: 14 feb 2024 @ 15:40
Avkastning: 11.80%
Forrige signal: feb 13 - 15:30
Forrige signal:
Avkastning: 0.53 %
Live Chart Being Loaded With Signals
Mesa Laboratories, Inc. develops, manufactures, and sells life sciences tools and quality control products and services in the United States, Europe, the Asia Pacific, and internationally...
Stats | |
---|---|
Dagens volum | 18 627.00 |
Gjennomsnittsvolum | 43 153.00 |
Markedsverdi | 556.61M |
EPS | $0 ( 2024-02-05 ) |
Neste inntjeningsdato | ( $2.33 ) 2024-05-24 |
Last Dividend | $0.160 ( 2023-11-29 ) |
Next Dividend | $0 ( N/A ) |
P/E | 607.00 |
ATR14 | $0.499 (0.48%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-04-02 | Sullivan John James | Sell | 450 | Non Qualified Stock Option |
2024-04-02 | Sakys John | Sell | 2 500 | Non Qualified Stock Option |
2024-04-02 | Owens Gary M | Sell | 5 000 | Non Qualified Stock Options |
2024-04-02 | Archbold Brian David | Sell | 420 | Non Qualified Stock Option |
2024-01-08 | Archbold Brian David | Sell | 290 | Non Qualified Stock Option |
INSIDER POWER |
---|
12.65 |
Last 100 transactions |
Buy: 73 301 | Sell: 52 584 |
Mesa Laboratories Inc Korrelasjon
10 Mest positive korrelasjoner |
---|
10 Mest negative korrelasjoner |
---|
Visste du det?
Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).
Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.
Mesa Laboratories Inc Økonomi
Annual | 2023 |
Omsetning: | $219.08M |
Bruttogevinst: | $133.69M (61.02 %) |
EPS: | $0.170 |
FY | 2023 |
Omsetning: | $219.08M |
Bruttogevinst: | $133.69M (61.02 %) |
EPS: | $0.170 |
FY | 2022 |
Omsetning: | $184.34M |
Bruttogevinst: | $109.09M (59.18 %) |
EPS: | $0.360 |
FY | 2021 |
Omsetning: | $133.94M |
Bruttogevinst: | $87.01M (64.97 %) |
EPS: | $0.660 |
Financial Reports:
No articles found.
Mesa Laboratories Inc Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
$0.160 (N/A) |
$0.160 (N/A) |
$0.160 (N/A) |
$0.160 (N/A) |
$0.160 (N/A) |
$0.160 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
Very Unsafe
High risk of being cut
Unsafe
Heightened risk of being cut
Borderline
Moderate risk of being cut
Safe
Unlikely to be cut
Very Safe
Very unlikely to be cut
First Dividend | $0.200 | 2003-11-26 |
Last Dividend | $0.160 | 2023-11-29 |
Next Dividend | $0 | N/A |
Payout Date | 2023-12-15 | |
Next Payout Date | N/A | |
# dividends | 81 | -- |
Total Paid Out | $11.06 | -- |
Avg. Dividend % Per Year | 0.19% | -- |
Score | 4.41 | -- |
Div. Sustainability Score | 7.61 | |
Div.Growth Potential Score | 5.87 | |
Div. Directional Score | 6.74 | -- |
Year | Amount | Yield |
---|---|---|
2003 | $0.200 | 3.07% |
2004 | $0.410 | 4.07% |
2005 | $0.500 | 3.85% |
2006 | $0.390 | 2.60% |
2007 | $0.340 | 1.80% |
2008 | $0.400 | 1.54% |
2009 | $0.410 | 2.27% |
2010 | $0.450 | 1.70% |
2011 | $0.490 | 1.63% |
2012 | $0.530 | 1.29% |
2013 | $0.570 | 1.08% |
2014 | $0.610 | 0.79% |
2015 | $0.640 | 0.80% |
2016 | $0.640 | 0.64% |
2017 | $0.640 | 0.52% |
2018 | $0.640 | 0.51% |
2019 | $0.640 | 0.31% |
2020 | $0.640 | 0.26% |
2021 | $0.640 | 0.23% |
2022 | $0.640 | 0.20% |
2023 | $0.640 | 0.37% |
2024 | $0 | 0.00% |
The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. However, its Dividend Growth Potential Score (DGPS) is only moderate, indicating limited growth potential. On the whole, the dividend outlook remains neutral, meriting close observation of both the company's financial health and growth prospects.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
OXSQ | Dividend Diamond | 2023-12-14 | Monthly | 21 | 9.10% | 8.50 |
PSEC | Dividend Royal | 2023-12-26 | Monthly | 21 | 7.04% | 8.50 |
SLVO | Dividend Royal | 2023-11-20 | Monthly | 12 | 10.77% | 8.50 |
QYLD | Dividend Royal | 2023-11-20 | Monthly | 11 | 7.50% | 8.50 |
GAIN | Dividend Royal | 2023-12-04 | Monthly | 20 | 8.19% | 8.50 |
GLDI | Dividend Royal | 2023-11-20 | Monthly | 12 | 7.15% | 8.50 |
OXLC | Dividend Royal | 2023-12-14 | Monthly | 14 | 10.00% | 8.50 |
HRZN | Dividend King | 2023-12-18 | Monthly | 15 | 6.60% | 8.45 |
USOI | Dividend Royal | 2023-11-20 | Monthly | 8 | 16.70% | 8.28 |
PFLT | Dividend King | 2023-11-15 | Monthly | 14 | 6.50% | 8.27 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | 0.00445 | 1.500 | 9.91 | 10.00 | [0 - 0.5] |
returnOnAssetsTTM | 0.00128 | 1.200 | 9.96 | 10.00 | [0 - 0.3] |
returnOnEquityTTM | 0.00241 | 1.500 | -1.084 | -1.626 | [0.1 - 1] |
payoutRatioTTM | 3.63 | -1.000 | 10.00 | -10.00 | [0 - 1] |
currentRatioTTM | 2.68 | 0.800 | 1.606 | 1.285 | [1 - 3] |
quickRatioTTM | 1.503 | 0.800 | 5.87 | 4.69 | [0.8 - 2.5] |
cashRatioTTM | 0.639 | 1.500 | 7.56 | 10.00 | [0.2 - 2] |
debtRatioTTM | 0.318 | -1.500 | 4.70 | -7.04 | [0 - 0.6] |
interestCoverageTTM | -2.03 | 1.000 | -1.862 | -1.862 | [3 - 30] |
operatingCashFlowPerShareTTM | 8.12 | 2.00 | 7.29 | 10.00 | [0 - 30] |
freeCashFlowPerShareTTM | 7.55 | 2.00 | 6.23 | 10.00 | [0 - 20] |
debtEquityRatioTTM | 0.586 | -1.500 | 7.66 | -10.00 | [0 - 2.5] |
grossProfitMarginTTM | 0.610 | 1.000 | 3.16 | 3.16 | [0.2 - 0.8] |
operatingProfitMarginTTM | -0.0438 | 1.000 | -2.88 | -2.88 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | 0.185 | 1.000 | -0.0812 | -0.0812 | [0.2 - 2] |
assetTurnoverTTM | 0.287 | 0.800 | -1.420 | -1.136 | [0.5 - 2] |
Total Score | 7.61 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | 587.03 | 1.000 | 10.00 | 0 | [1 - 100] |
returnOnEquityTTM | 0.00241 | 2.50 | -0.697 | -1.626 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | 7.55 | 2.00 | 7.48 | 10.00 | [0 - 30] |
dividendYielPercentageTTM | 0.620 | 1.500 | 10.00 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | 8.12 | 2.00 | 7.29 | 10.00 | [0 - 30] |
payoutRatioTTM | 3.63 | 1.500 | 10.00 | -10.00 | [0 - 1] |
pegRatioTTM | 1.693 | 1.500 | 2.05 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | 0.206 | 1.000 | 7.36 | 0 | [0.1 - 0.5] |
Total Score | 5.87 |
Mesa Laboratories Inc
Mesa Laboratories, Inc. develops, manufactures, and sells life sciences tools and quality control products and services in the United States, Europe, the Asia Pacific, and internationally. The company's Sterilization and Disinfection Control segment manufactures and sells biological, cleaning, and chemical indicators that are used to assess the effectiveness of sterilization and disinfection processes in the hospital, dental, medical device, and pharmaceutical industries. This segment also provides testing and laboratory services primarily to the dental industry. Its Biopharmaceutical Development segment develops, manufactures, and sells automated systems for protein analysis (immunoassays) and peptide synthesis solutions. This segment's solutions include protein analysis comprising analysis equipment, CDs, kits, and buffers; and peptide synthesizers that enables to automate chemically synthesized peptides that are used in the creation of peptide therapies, biomaterials, cosmetics, and general research. The company's Calibration Solutions segment designs, manufactures, and markets quality control and calibration products to measure or calibrate temperature, pressure, pH, humidity, and other such parameters used for health and safety purposes in the hospital, medical device manufacturing, pharmaceutical manufacturing, and various laboratory and healthcare environments. This segment's products include continuous monitoring systems, dialysate meters and consumables, data loggers, gas flow calibration and air sampling equipment, and torque testing systems. Its Clinical Genomics segment develops, manufactures, and sells genetic analysis tools that include MassARRAY system and consumables, including chips, panels, and chemical reagent solutions used by clinical labs to perform genomic clinical testing in several therapeutic areas, such as newborn screenings, pharmacogenetics, and oncology. The company was incorporated in 1982 and is headquartered in Lakewood, Colorado.
Om Live Signaler
Live Trading signaler pa denne siden er ment til å hjelpe deg i beslutningsprossessen for når du bør KJØPE eller SELGE NA. Signalene har opp mot 1-minutt forsinkelse; som med alle andre indikatorer og signaler, er det en viss sjanse for feil eller feilkalkuleringer.
Live signalene er kun veiledende, og getagraph.com tar ikke noen form for ansvar basert pa handlinger gjort på disse signalene som beskrevet i Terms of Use. Signalene er basert på en rekke indikatorer og påliteligheten vil variere sterke fra aksje til aksje.